Creatine Kinase-MB

Abstract
Creatine kinase (CK)-MB is the enzyme currently used as the definitive serum marker for the diagnosis or exclusion of acute myocardial infarction (AMI). This article reviews the characteristics of CK-MB, the methods and limitations of the new monoclonal anti-CK-MB antibody-based immunoassays, information on the diagnostic accuracy, clinical implications of serial and single enzyme levels, and recommendations for the optimal use of CK-MB. In addition, the role of serum CK-MB in monitoring reperfusion following thrombolytic therapy for patients with AMI is discussed.

This publication has 0 references indexed in Scilit: